<DOC>
	<DOCNO>NCT00092014</DOCNO>
	<brief_summary>This study evaluate compare effect Alendronate Risedronate treat woman postmenopausal osteoporosis . The primary hypothesis study postmenopausal woman osteoporosis , treatment oral alendronate 70 mg weekly produce mean percent increase baseline hip trochanter bone mineral density ( BMD ) 12 24 month great observed oral risedronate 35 mg weekly .</brief_summary>
	<brief_title>A Study Evaluate Compare Alendronate Risedronate Bone Mineral Density Women With Postmenopausal Osteoporosis ( MK-0217-211 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Women postmenopausal osteoporosis Bilateral hip replacement Esophageal abnormalities Metabolic bone disease ( example Vitamin D deficiency ) Medications would affect breakdown buildup bone turnover</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>